The DMD Genetic Therapy Group


The primary mission of the DMD Genetic Therapy Group at the Department of Human Genetics (chaired by Prof. Dr. Silvère van der Maarel) of the Leiden University Medical Center is the development of the "exon skipping" approach for Duchenne Muscular Dystrophy (DMD). The project started in 1998 and is currently supervised by Dr. Annemieke Aartsma-Rus, after Dr. Judith C.T. van Deutekom left in February 2007 to work as Head of research for the biotech company Prosensa. B.V. (Leiden, the Netherlands). In a joint effort the DMD genetic therapy group and Prosensa are developing the exon skip approach for DMD.

We have created a special section on our website for patients and parents, where we try to explain the rationale of the exon skipping approach in simple terms. If anything is unclear, please do not hesitate to contact us for further information. This will help us to improve these pages.



Dr. Annemieke Aartsma-Rus

DMD Genetic Therapy Group

Dept. of Human Genetics,

Leiden University Medical Center, Div. 5

Postzone S4-P

PO Box 9600

2300 RC Leiden

The Netherlands

Tel. +31-71-5269436

Fax +31-71-5268285